Skip to main content
CLARITY PHARMACEUTICALS LTD logo

CLARITY PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · CU6 ISIN · AU0000165375 LEI · 894500870CF75LRT6F56 ASX Professional, scientific and technical activities
Open in API
Filings indexed 481 across all filing types
Latest filing 2026-05-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX CU6

About CLARITY PHARMACEUTICALS LTD

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve treatment outcomes for children and adults with cancer. The company utilizes its proprietary SAR Technology platform, which employs highly stable chelators to link copper isotopes to targeting molecules. This platform supports a Targeted Copper Theranostics (TCT) approach, pairing Copper-64 for high-resolution PET imaging with Copper-67 for targeted radiotherapy. Key pipeline assets include SAR-bisPSMA for prostate cancer, SAR-Bombesin for various solid tumors, and SARTATE for neuroblastoma and neuroendocrine tumors. By leveraging the physical properties of copper isotopes, the company aims to overcome logistical and manufacturing limitations associated with traditional radiopharmaceuticals, enabling centralized distribution and broader patient access to precision oncology treatments.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - CU6 8 pages 24.3KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX Appendix 2A “Application for quotation of securities,” detailing the conversion of options into new ordinary shares and the application for listing those securities. It is specifically an announcement of new share issues and a change in capital structure, fitting the definition of a Share Issue/Capital Change.
2026-05-19 English
Cleansing Notice 1
Share Issue/Capital Change Classification · 90% confidence The document is an ASX media release titled “On-Sale Cleansing Notice Under Section 708A(5)(E) Corporations Act,” detailing the issuance of 713,157 fully paid ordinary shares upon option exercise and related disclosure compliance under the Corporations Act. It is not a financial report or AGM material but an announcement of a share issuance/capital change. This matches the “Share Issue/Capital Change” category.
2026-05-19 English
Clarity receives $9.8 million R&D tax incentive refund 1
Regulatory Filings Classification · 81% confidence The document is an ASX announcement notifying investors that Clarity Pharmaceuticals has received a governmental R&D tax incentive refund. It does not contain financial statements or qualify as an earnings release, interim report, or funding transaction like a share issue or debt placement. It is a general regulatory announcement about a grant/refund, which does not fit into any specific category. Therefore, it falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-05-13 English
Quarterly Activities/Appendix 4C Cash Flow Report 32 pages 3.1MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activity Report' and references the quarter ending 31 March 2026, indicating it is a periodic report covering a fiscal quarter. It contains detailed financial and operational highlights, clinical trial updates, manufacturing agreements, and management changes. The length is substantial (15,000 characters), and it includes substantive financial and operational data rather than just an announcement or summary. The content aligns with a comprehensive interim or quarterly report rather than a brief earnings release or an announcement of a report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-29 English
Change of Director's Interest Notice - Parker 4 pages 458.8KB
Director's Dealing Classification · 91% confidence The document is an ASX announcement detailing a director’s sale of shares, including an Appendix 3Y “Change of Director’s Interest Notice” under ASX Listing Rule 3.19A.2. It reports the personal share transaction of the Managing Director, including securities held before and after the trade. This matches the definition of a Director’s Dealing filing.
2026-04-21 English
Clarity signs a Commercial Manufacturing Agreement 3 pages 213.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 14 April 2026 about Clarity Pharmaceuticals signing a Commercial Manufacturing Agreement with Nucleus RadioPharma. It details the agreement's scope, manufacturing capabilities, and strategic importance for future commercial launch of a radiopharmaceutical product. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a commercial manufacturing agreement, which fits the category of Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes. The document length is 8870 characters, which is substantial and contains detailed information about the agreement, not just a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2026-04-13 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.